Organon is a global biopharmaceutical company and was founded in 1923 as Zwanenberg-Organon. The company mainly focuses on gynaecology specifically contraception, fertility, hormone replacement therapy and osteoporosis prevention. The company also has an interest in mental health, anaesthesiology, atherothrombosis and immunology. Organon’s product portfolio includes the third-generation oral contraceptives Marvelon and Mercilon. The company will invest more than 19.5% of its annual sales in research and development.